WHO ICTRP trial
The effectivness and safety of ponatinib administered in combination with…
EUCTR2019-004540-29-CZ · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2019-004540-29-CZ |
|---|---|
| Public title | The effectivness and safety of ponatinib administered in combination with reduced chemotherapy in treatment of acute lymphoblastic leukemia in adults. |
| Scientific title | Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia - Pona-CELL |
| Primary sponsor | Ústav hematologie a krevní transfuze |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Czech Republic |
| Conditions | NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA MedDRA version: 21.0 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C]… |
| Interventions | Trade Name: ICLUSIG 15 mg film-coated tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ponatinib CAS Number: 943319-70-8 Other descriptive name: PONATINIB Concentration unit: mg milligram(s) Concentration type: range… |
| Registration date | Jul 7, 2020 |
| Target size | 32 |
| Secondary IDs | Pona-CELL |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: